

In the Drawings:

Please amend the drawings denominated "Figure 12", "Figure 14", "Figure 16", "Figure 17", and "Figure 20" as indicated in the attached marked up drawings.

REMARKS

This amendment is being submitted under 37 CFR §1.312 following the mailing of a Notice of Allowance and Fees Due in this case on 2 December 2002, and prior to payment of the issue fee. Subsequent to receiving the Notice, Applicants noticed several minor errors in the drawings and the brief description of the drawings. Applicants respectfully request entry of the present amendment in order to correct these errors.

Extraneous reference characters were noticed in the drawings denominated "Figure 12", "Figure 14", "Figure 16", "Figure 17", and "Figure 20". The brief description of the drawing denominated "Figure 17" has also been amended to correctly correspond to the figure. Prior to amendment, the brief description of Figure 17 referred to panels A to F, which are not present in the drawing.

Attached hereto is a sheet titled, "Version With Markings to Show Changes Made", which depicts the changes made to the instant application by the current amendment.

Respectfully submitted,

DORSEY & WHITNEY LLP

Dated: 12/20/02

BY:

Robin M. Silva

Robin M. Silva, Reg. No. 38,304
Filed under 37 C.F.R. § 1.34(a)

Customer Number: 32940
Dorsey & Whitney LLP
Intellectual Property Department
Four Embarcadero Center, Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989
Facsimile: (415) 398-3249

Version With Markings to Show Changes Made

In the Specification:

At page 7, line 6:

Figure 17 shows the results showing regulation of the cytoskeleton by Tnik. [Figures 17A-17F show the] The results showing inhibition of cell spreading by Tnik. 0.4 μ g of GFP was co-transfected into Phoenix-A cells with 3 μ g of Vector, Tnik(WT), Tnik(KM), Tnik(N1), Tnik(C1) or JNK2. 24 hours after transfection, cells were examined under fluorescent microscope.

RECEIVED
JAN 07 2003
TECH CENTER 1600/2900